A Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception

Trial ID or NCT#

NCT00995150

Status

recruiting iconRECRUITING

Purpose

The primary objective of this study is to assess the efficacy of a levonorgestrel-releasing intrauterine system (LNG20) in nulliparous and parous females of child-bearing potential who request long-term, reversible contraception for up to 10 years.

Official Title

A Phase 3, Multi-Center, Open-Label Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception

Eligibility Criteria

Ages Eligible for Study: 16 Years to 45 Years
Sexes Eligible for Study: Female
Accepts Healthy Volunteers: Yes
Inclusion Criteria:
  1. - Healthy women requesting contraception - 16-35 years old - Cohort 36-45 years old - Sexually active
Exclusion Criteria:
  1. - Currently pregnant, pregnant within 4 weeks prior to study entry or planning pregnancy within 24 months of study entry - Currently breastfeeding - Current persistent, abnormal vaginal bleeding
View All Criteria
Show Less

Investigator(s)

Paul D. Blumenthal, MD, MPH
Paul D. Blumenthal, MD, MPH
Obstetrician and Gynecologist (OB-GYN), Family planning specialist
Professor of Obstetrics and Gynecology (Gynecology-Family Planning) at the Stanford University Medical Center, Emeritus

Contact us to find out if this trial is right for you.

Contact

Kathryn Batham
650-724-7826

SEND MESSAGE

View on ClinicalTrials.gov